Literature DB >> 30341682

Pyrotinib: First Global Approval.

Hannah A Blair1.   

Abstract

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30341682     DOI： 10.1007/s40265-018-0997-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  5 in total

Review 1.  Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Authors:  Noam Pondé; Mariana Brandão; Georges El-Hachem; Emilie Werbrouck; Martine Piccart
Journal:  Cancer Treat Rev       Date:  2018-05-02       Impact factor: 12.111

2.  Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Authors:  Fei Ma; Qiao Li; Shanshan Chen; Wenjie Zhu; Ying Fan; Jiayu Wang; Yang Luo; Puyuan Xing; Bo Lan; Meiying Li; Zongbi Yi; Ruigang Cai; Peng Yuan; Pin Zhang; Qing Li; Binghe Xu
Journal:  J Clin Oncol       Date:  2017-05-12       Impact factor: 44.544

3.  Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.

Authors:  Xin Li; Changyong Yang; Hong Wan; Ge Zhang; Jun Feng; Lei Zhang; Xiaoyan Chen; Dafang Zhong; Liguang Lou; Weikang Tao; Lianshan Zhang
Journal:  Eur J Pharm Sci       Date:  2017-01-21       Impact factor: 4.384

4.  Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.

Authors:  Yunting Zhu; Liang Li; Ge Zhang; Hong Wan; Changyong Yang; Xingxing Diao; Xiaoyan Chen; Lianshan Zhang; Dafang Zhong
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-08-07       Impact factor: 3.205

Review 5.  HER2-positive breast cancer: Current and new therapeutic strategies.

Authors:  Santiago Escrivá-de-Romaní; Miriam Arumí; Meritxell Bellet; Cristina Saura
Journal:  Breast       Date:  2018-04-06       Impact factor: 4.380
  5 in total
  41 in total

Review 1.  The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.

Authors:  Jordyn Kreutzfeldt; Brett Rozeboom; Nandini Dey; Pradip De
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 2.  Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Authors:  Janakiraman Subramanian; Archana Katta; Ashiq Masood; Dashavantha Reddy Vudem; Rama Krishna Kancha
Journal:  Oncologist       Date:  2019-07-10

Review 3.  The changing treatment of metastatic her2-positive breast cancer.

Authors:  Maria Mitsogianni; Ioannis P Trontzas; Georgia Gomatou; Stephanie Ioannou; Nikolaos K Syrigos; Elias A Kotteas
Journal:  Oncol Lett       Date:  2021-02-12       Impact factor: 2.967

4.  Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial.

Authors:  Wei Wang; Lu Wang; Jin-Yi Chang; Fen Hu; Jin-Yin Yan; Juan Zhang; Yong-Ping Liang; Hui-Wen Zhang; Hong-Peng Wu; Hai-Feng Cai
Journal:  Gland Surg       Date:  2022-04

5.  Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.

Authors:  Qi Li; Yanyan Wang; Mingzhi Zhu; Yuanting Gu; Yajing Tang
Journal:  Gland Surg       Date:  2021-12

6.  Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.

Authors:  Xiaorong Zhong; Ping He; Jie Chen; Xi Yan; Bin Wei; Zhang Zhang; Hong Bu; Jing Li; Tinglun Tian; Qing Lv; Xiaodong Wang; Hongjiang Li; Jing Wang; Juan Huang; Jiaojiao Suo; Xiaoxiao Liu; Hong Zheng; Ting Luo
Journal:  Gland Surg       Date:  2022-01

7.  Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.

Authors:  Ruibin Liu; Shaoqi Zhan; Ye Che; Jana Shen
Journal:  J Med Chem       Date:  2021-10-14       Impact factor: 7.446

8.  Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer.

Authors:  Chunyu Tian; Minghui Wang; Hancheng Liu; Jianping Liu; Mengze Xu; Lihui Ma
Journal:  Ir J Med Sci       Date:  2022-07-13       Impact factor: 2.089

9.  The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer.

Authors:  Chaokun Wang; Shuzhen Deng; Jing Chen; Xiangyun Xu; Xiaochen Hu; Dejiu Kong; Gaofeng Liang; Xiang Yuan; Yuanpei Li; Xinshuai Wang
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244

10.  Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults.

Authors:  Yueyue Liu; Qian Zhang; Chao Lu; Wei Hu
Journal:  Drug Des Devel Ther       Date:  2021-06-10       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.